💊 Wanbury Ltd: This Pharma Stock Just Delivered 70% ROE – Magic Molecule or Margin Mirage?

🟢 1. At a Glance

Wanbury Ltd is a ₹874 Cr microcap pharma player with sky-high ROE (70%), improving margins, and a breakout FY25 performance. But beneath that profitable pill lies some bitter aftertaste—76% promoter pledge, low interest cover, and a history of financial volatility. Is this finally the turnaround… or another placebo rally?

🧪 2. Hook – “Debt, Drama, and a Dose of Iron”

Let’s face it: Wanbury has been a pharma penny stock refugee for a decade. And now it’s suddenly showing signs of life?

The company recently launched Wanbury C RED, a next-gen iron supplement. It posted ₹31 Cr PAT in FY25 (vs ₹-10 Cr in FY23), OPM hit 13%, and FY25 EPS surged to ₹9.32.

But this isn’t just about pills. It’s also about fines for audit delays, promoter pledging, and shady other income swings.

So, what changed?

🧬 3. WTF Do They Even Do?

Wanbury operates in two key segments:

💊 1. APIs (Active Pharmaceutical Ingredients)

• Serves 50+ countries
• Focus on Metformin, Tramadol, Salsalate
• Major export-driven biz

💉 2. Formulations (Domestic Branded Generics)

• Pan-India sales team
• Focused on therapies like:
  • Iron deficiency
  • CNS (painkillers)
  • Cardiovascular & diabetology
• Recent expansion via Wanbury C RED (iron + Vit C combo)

🧪 They also emphasize R&D, but no proprietary blockbuster drug yet.

📊 4. Financials – Profit, Margins, ROE, Growth